The sharp increase in IINN's stock price is directly attributed to the announcement of the U.S. Patent approval for its VORTX technology. This approval not only validates the company's technological innovation but also positions it as a potential disruptor in the healthcare technology sector, particularly in blood oxygenation. The market's positive reaction reflects investor confidence in the company's future growth prospects and its ability to enhance patient care with its new technology.